SN 2310

Drug Profile

SN 2310

Alternative Names: SN 2310 Injectable Emulsion; SN2310; TOCOSOL Camptothecin

Latest Information Update: 20 Apr 2012

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Sonus Pharmaceuticals
  • Developer OncoGenex Pharmaceuticals
  • Class Antineoplastics; Camptothecins
  • Mechanism of Action DNA topoisomerase I inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • Available For Licensing Yes

Highest Development Phases

  • Discontinued Solid tumours

Most Recent Events

  • 30 Mar 2011 Discontinued - Phase-I for Solid tumours in USA (IV)
  • 10 Nov 2008 OncoGenex Pharmaceuticals completes enrolment in its phase1 trial for solid tumours in USA
  • 21 Aug 2008 OncoGenex Technologies has merged with Sonus Pharmaceuticals to form OncoGenex Pharmaceuticals
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top